The U.S. is halting distribution of sotrovimab, a COVID-19 antibody made by GlaxoSmithKline and Vir Biotechnology, in regions where the omicron subvariant BA.2 has become dominant in response to data suggesting the treatment is ineffective against the strain.
Read the full post on Becker's Hospital Review - Healthcare News
